[Reported by “Radar M” on May 22 (15:55)] The Growth of the Domestic Skincare Industry

Interview Highlights with Kang Hee-chul, CEO of GFC Life Sciences

GFC Life Sciences is at the forefront of K-beauty innovation, developing fourth-generation skin boosters using plant-derived exosome materials. CEO Kang Hee-chul discussed their strategic move from KONEX to the KOSDAQ market, underscoring their groundbreaking technology.

Key Developments:

• Exosome Technology: GFC Life Sciences is harnessing exosomes, which improve skin health by regenerating damaged skin and enhancing natural recovery processes.

• Market Growth: The exosome market is projected to grow at a CAGR of 24.8%. GFC Life Sciences plans to leverage their comprehensive exosome technologies to launch next-gen skin boosters.

• Financial Outlook: The company reported 16.8 billion won in sales last year, anticipating a 36.8% increase in sales and a 184.8% rise in operating profit this year.

• Public Offering: A public offering aims to raise 9.6 to 12 billion won. Funds will support factory expansion, debt repayment, and R&D.

• Timeline: Institutional investor demand forecasting runs from May 30 to June 9, with public subscriptions on June 12-13. Daishin Securities is managing the listing, scheduled for June 20.